Mark Sulkowski, MD, is a Professor of Medicine, the Senior Associate Dean for Clinical Trials, and the Director of the Office of Clinical Trials at the Johns Hopkins University School of Medicine. He also serves as the Director of the Division of Infectious Diseases at the Johns Hopkins Bayview Medical Center, a Deputy Director for the Johns Hopkins Institute for Clinical and Translational Research, and the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine. He received his MD from Temple University School of Medicine, Philadelphia, PA, pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC, and completed his Fellowship in Infectious Diseases at the Johns Hopkins University School of Medicine.
Dr. Sulkowski directs a multi-disciplinary clinical and translational research program related to hepatitis B, hepatitis C, and steatotic liver disease in persons with and without HIV co-infection. He has led over 200 clinical trials, serving as the global principal investigator for the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins. He is the past chair of the Hepatitis Transformative Sciences Group of the NIH-funded ACTG (Advancing Clinical Therapeutics Globally) network. where he led translational studies of liver disease in people with HIV. As the past recipient of the NIH K24 Midcareer Investigator Awards in Patient-Oriented Research, Dr. Sulkowski has mentored more than 50 investigators globally and is committed to training the next generation of clinical researchers. He is an elected member of the American Society for Clinical Investigation and the American Association of Physicians.